Trendlines Group (SG:42T) has released an update.
Trendlines Group has announced significant developments within its portfolio, including Vensica Medical securing $11 million for bladder treatment trials and ElastiMed appointing a key industry figure to its board. Additionally, iRen-MEDICAL has launched an investment campaign for its innovative dialysis system. These updates reflect the company’s dynamic growth and strategic advancements in the medical sector.
For further insights into SG:42T stock, check out TipRanks’ Stock Analysis page.
